Coherus Biosciences Inc. (CHRS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Coherus Biosciences Inc. (CHRS:NASDAQ), powered by AI.

Current Price
$1.40
Sector
Healthcare
What is the Coherus Biosciences Inc. stock price forecast?

Coherus Biosciences Inc. is currently trading at $1.40. View real-time AI analysis on Alpha Lenz.

What is Coherus Biosciences Inc. insider trading activity?

View the latest insider trading data for Coherus Biosciences Inc. on Alpha Lenz.

What is Coherus Biosciences Inc.'s P/E ratio?

View Coherus Biosciences Inc.'s valuation metrics on Alpha Lenz.

Coherus Biosciences Inc.

NASDAQ · CHRS
$1.40-0.02(-1.41%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Coherus Biosciences Inc.'s future dividend policy...
Alpha Chat Insight

Coherus Biosciences Inc.'s ROE is -473.5%. Explore profitability and growth together.

Ask for details

Company Overview

Coherus Biosciences Inc. is a biotechnology company focused on developing, manufacturing, and commercializing biosimilar products. Biosimilars are highly similar to existing, approved biological medicines with no clinically meaningful differences in terms of safety or efficacy. Coherus Biosciences aims to provide more accessible biological therapeutics in key therapeutic areas such as oncology, ophthalmology, and immunology. By doing so, the company addresses the need for more cost-effective treatment options and aims to contribute to the sustainability of healthcare systems globally. Coherus Biosciences operates within a highly regulated market, collaborating with healthcare providers, payers, and patients to enhance treatment options and availability. Founded in 2010 and headquartered in Redwood City, California, the company leverages its specialized research and development capabilities to expand its portfolio, providing competitive alternatives to high-cost biologics and playing a significant role in the biotechnology and healthcare sectors by fostering innovation and reducing healthcare costs.

CEOMr. Dennis M. Lanfear
SectorHealthcare
IndustryBiotechnology
Employees228

Company Statistics

FY 2025

Profile

N/AMarket Cap
$42.17MRevenue
0.00Shares Out
228Employees

Margins

67.24%Gross
-403.58%EBITDA
-429.51%Operating
-434.23%Pre-Tax
398.43%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

-41.54%Rev 3Yr
-38.41%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
4.91%Net Inc 5Yr

Returns

47.54%ROA
-473.47%ROE
-49.27%ROIC

Financial Health

$88.88MCash & Cash Equivalents
$108.45MNet Debt
323.42%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Coherus Biosciences Inc. (ticker: CHRS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 228 employees.

The current price is $1.4 with a P/E ratio of -x and P/B of -x.

ROE is -473.47% and operating margin is -429.51%. Annual revenue is $42M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Coherus Biosciences Inc. (CHRS) Stock Forecast 2026 $1.40 — Price, Financials & Analyst Targets | Alpha Lenz